Neuropathy News and Research

RSS

NeuroMetrix announces business and financial highlights for second quarter

NeuroMetrix, Inc. (the "Company"), a medical device company focused on the treatment of the neurological complications of diabetes, today reported business and financial highlights for the second quarter ended June 30, 2013.

25 Jul 2013

FDA takes action to remove illegal diabetes products from market

The U.S. Food and Drug Administration is taking action to remove from the market illegal products, including some labeled as dietary supplements, that claim to mitigate, treat, cure or prevent diabetes and related complications.

24 Jul 2013

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the University of Maryland, Baltimore for a novel drug delivery platform, Nano-Polymer-Drug Conjugate Systems.

17 Jul 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

Patients suffering from severe Charcot-Marie-Tooth disease can benefit from reconstructive surgery

For patients suffering from Charcot-Marie-Tooth disease - a surprisingly common neurological disorder that can cause the feet to become weak and contorted - surgery is considered a last resort. But for patients like Elissa Williams and her brother Kyle, surgery can bring an end to crippling pain and lead to active lives with feet facing forward and balanced on the ground.

12 Jul 2013

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive top-line results from its ongoing Phase I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis.

12 Jul 2013

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.

9 Jul 2013

Pitt researchers propose mathematical model that examines multiple walking patterns in older adults

Older adults diagnosed with brain disorders such as Parkinson's disease often feel a loss of independence because of their lack of mobility and difficulty walking.

3 Jul 2013

Study finds that triple therapy corrects two core defects in type 2 diabetes

Patients with type 2 diabetes fare significantly better if they are started on three medications at the time of diagnosis than if they are prescribed a single drug and have other therapies added later, a San Antonio researcher said June 22 at the 73rd Scientific Sessions of the American Diabetes Association in Chicago.

25 Jun 2013

Weight loss does not reduce heart disease risks among Type 2 diabetes patients: Study

A landmark study investigating the long-term effects of weight loss on the risks of cardiovascular disease among patients with Type 2 diabetes has now concluded, with significant results to be published today in the New England Journal of Medicine.

25 Jun 2013

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi announced today that the first Phase 3 study results for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus.

24 Jun 2013

NACC recommendations address established pain therapies and preview potential future advances

Recommendations of the Neuromodulation Appropriateness Consensus Committee (NACC), announced at the 11th World Congress of the International Neuromodulation Society (INS), address established therapies and preview emerging and potential future advances.

13 Jun 2013

Massachusetts Eye and Ear enrolls deaf children in new clinical trial of Auditory Brainstem Implant

The Massachusetts Eye and Ear Infirmary, a Harvard Medical School teaching affiliate, is now enrolling a select group of deaf infants and children in a new FDA-approved clinical trial of an Auditory Brainstem Implant.

12 Jun 2013

Hybrid molecular imaging technique helps doctors identify diabetic foot infection

Researchers are kick-starting better diabetic foot care and promoting reduced radiation dose with a new take on a hybrid molecular imaging technique. By targeting both bone cell activity and immune response and improving imaging data interpretation, doctors can better distinguish diabetic foot infection from another common foot condition that often requires an additional bone-marrow scan for definitive diagnosis, say researchers presenting a study at the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting.

12 Jun 2013

BioDelivery Sciences International submits BUNAVAIL NDA to FDA

BioDelivery Sciences International, Inc. announced today that it engaged in a positive pre-New Drug Application meeting with the U.S. Food and Drug Administration regarding BUNAVAIL for the maintenance treatment of opioid dependence.

10 Jun 2013

First consensus guidelines for use of neurostimulation in chronic pain

Recognizing that treatment of chronic pain can be confounding, the Neuromodulation Appropriateness Consensus Committee, an international group of more than 60 leading pain specialists, has created the first consensus guidelines for the use of neurostimulation in chronic pain.

10 Jun 2013

Patented nicotinamide riboside launched by Chromadex

ChromaDex Corporation, an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today the launch of NIAGEN, its novel, patented, branded nicotinamide riboside.

29 May 2013

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.

23 May 2013

Viewpoints: Sebelius' 'ethical line'; As tricky phase of health law approaches, concerns about exchanges opening on time

One of the biggest questions hanging over the health-care system is how many young Americans will sign up for coverage once the Affordable Care Act begins to phase in this October. If too few buy insurance on the markets that the government is creating, insurance companies would be stuck covering primarily the old and the sick. They would have to pay out more per customer.

21 May 2013

Television actor hosts latest free patient education DVD and guidebook on epilepsy

Television actor and "Dancing with the Stars" winner John O'Hurley is the host of Epilepsy: A Guide for Patients and Families, the latest free patient education DVD and guidebook produced by the American Academy of Neurology and its foundation, the American Brain Foundation.

20 May 2013